critics News
Most Popular critics Story
PDUFA debate highlights drug safety issues
The House is expected to take up PDUFA legislation soon, and that has renewed the debate over the impact of the fees and the possibility of new requirements related to pharmacovigilance. PDUFA, which has to be reauthorized every five years, has been a hot topic of late. Critics maintain that PDUFA has given the drug industry …
Read more...Latest Headlines
- October 5, 2007
- July 17, 2007
- July 4, 2007
- June 28, 2007
- November 6, 2006
- September 6, 2006
- September 5, 2006
- August 28, 2006
- August 8, 2006
- July 20, 2006
- July 17, 2006
- July 10, 2006
- July 2, 2006
- May 3, 2006
- April 23, 2006
- April 23, 2006
- March 15, 2006
- February 23, 2006
- November 27, 2005
- November 20, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
